彭雁南,王 鵬,宋 妮,張秀麗,任素梅,李 明
(中國海洋大學(xué)醫(yī)藥學(xué)院海洋藥物教育部重點實驗室,山東 青島266003)
甾體皂苷是很多傳統(tǒng)藥用植物的活性成分,具有抗腫瘤、抗病毒、抗炎、抗菌、免疫調(diào)節(jié)等多種多樣的生物活性[1]。但由于一種植物中所含的皂苷種類多且結(jié)構(gòu)類似,有的成分含量又很少,很難分離出一定量的單一成分,從而限制了它的藥理活性研究及在臨床上的應(yīng)用?;瘜W(xué)合成可以高效便捷的得到具有特定結(jié)構(gòu)的甾體皂苷,目前的合成方法大多通過多步的保護(hù)基操作來實現(xiàn)。區(qū)域選擇性保護(hù)基操作和糖苷化由于經(jīng)濟(jì)便捷和高效,受到了越來越多關(guān)注和應(yīng)用,已有多種區(qū)域選擇性糖苷化方法[2-5]被報道。半乳糖是甾體皂苷中常見的糖基,如甾體皂苷 Laxnmin B[6]中帶有β-DGlcp-(1→4)-[α-L-Rhap-(1→2)]-β-D-Gal p 糖鏈,澳洲茄 堿[7]中 帶 有 β-D-Glcp-(1→3)-[α-L-Rhap-(1→2)]-β-D-Gal p 糖鏈,因此發(fā)展對半乳糖皂苷的選擇性保護(hù)和糖苷化方法對合成這類化合物具有重要意義。本文報道對半乳糖薯蕷皂苷進(jìn)行選擇性特戊?;Wo(hù)及其選擇性糖苷化反應(yīng)的研究。
所用試劑:TMSOTf、DMAP、CCl3CN、DBU 均為Aldrich-Sigma、Acros公司產(chǎn)品,直接用于反應(yīng);二氯甲烷用前以氫化鈣回流重蒸;所用石油醚為60~90℃沸程。未經(jīng)特殊說明,其它均為普通國產(chǎn)分析純試劑。用以檢測反應(yīng)進(jìn)程的薄層色譜(TLC)為煙臺化學(xué)工業(yè)研究所產(chǎn)薄層色譜硅膠預(yù)制板(硅膠粒度10~40μm)。顯色液為8%濃硫酸甲醇溶液。柱層析所用硅膠購自青島海洋化工廠分廠,規(guī)格為300~400目。
主要實驗儀器JEOL-ECP-600NMR核磁共振波
譜儀;JASCO P-1020數(shù) 顯 旋 光 儀;Q-TOF 質(zhì) 譜 儀;EYELA低溫反應(yīng)器。
1.2.1 化合物2的合成 向裝有新活化的4A分子篩的兩頸瓶中加入薯蕷皂苷元(207mg,0.50mmol)和半乳糖三氯亞胺酯給體1(517mg,0.70mmol),無水二氯甲烷(10.0mL)溶解樣品,室溫攪拌30min,加入三甲基硅基三氟甲磺酸酯(以下簡稱TMSOTf)(10μL,0.05mmol),攪拌反應(yīng)30min后,加入兩滴三乙胺淬滅反應(yīng),抽濾,減壓濃縮,硅膠柱層析,(石油醚∶乙酸乙酯=5∶1),減壓濃縮得白色固體2(438mg,0.44mmol,88%)。1H NMR (CDCl3,600MHz)δ8.02(dd,2H,J=7.2,1.1Hz),7.95(d,2H,J=7.2Hz),7.89(dd,2H,J=7.1,1.1Hz),7.71(dd,2H,J=7.1,1.1Hz),7.54-7.29(m,10H),7.17(dd,2H,J=12.6,4.9Hz),5.91(d,1H,J=3.3Hz),5.70(dd,1H,J=10.4,8.2Hz),5.52(dd,1H,J=10.4,3.8Hz),5.14(d,1H,J=5.0Hz),4.84(d,1H,J=8.3Hz),4.60(dd,1H,J=11.0,6.6Hz),4.23-4.36(m,3H),3.48(m,1H),3.41-3.27(m,2H),0.90(d,3H,J=7.1Hz),0.85(s,3H),0.71(d,3H,J=6.1Hz),0.69(s,3H).
1.2.2 化合物3的合成 稱取化合物2(2.87g,2.9mmol)于單口瓶中,加入甲醇(20.0mL),二氯甲烷(20.0mL)溶解樣品,加入催化量的甲醇鈉,室溫反應(yīng)過夜,用酸性樹脂調(diào)節(jié)pH值到弱酸性,過濾,旋蒸濃縮得白色固體,乙醚洗滌,抽濾得白色固體3(1.46g,2.53mmol,87%)。
1.2.3 化合物4的合成 稱取半乳糖薯蕷皂苷3(600mg,1.04mmol)于兩頸甁中,加入二氯甲烷(20.0mL)和2,4,6-三甲基吡啶(collidine)(5.0mL)溶解樣品,室溫下緩慢滴加特戊酰氯(PivCl)(385μL,3.12mmol),升溫至50℃反應(yīng)5.0h,反應(yīng)完畢后,加入少量甲醇淬滅反應(yīng),用二氯甲烷稀釋反應(yīng)液,分別用1mol·L-1鹽酸,飽和碳酸氫鈉,蒸餾水,飽和食鹽洗,無水硫酸鈉干燥,抽濾,硅膠柱層析(二氯甲烷∶甲醇=50∶1~25∶1),濃縮得白色固體4(464mg,0.70 mmol,68%)。[α]27D-72.3°(c 0.34,CHCl3);1HNMR(600MHz,pyridine-d5)δ5.32 (d,1H,J=4.9Hz),4.85 (m,2H),4.71(dd,1H,J=11.0,4.9Hz),4.53(dd,1H,J=14.3,7.1Hz),4.41(t,1H,J=9.4Hz),4.35(d,1H,J=2.8Hz),4.17(dd,1H,J=9.3,3.3Hz),4.08(t,1H,J=6.6Hz),3.90(m,1H),3.55(d,1H,J=11.0Hz),3.46(t,1H,J=11.0Hz),1.23(s,9H),1.12(d,3H,J=7.1Hz),0.92(s,3H),0.82(s,3H),0.67(d,3H,J=5.5Hz);13C NMR(150MHz,pyridine-d5)δ177.8,140.8,121.5,109.0,103.0,80.9,78.3,74.9,73.2,72.1,69.7,66.6,64.3,62.7,56.4,50.1,41.7,40.2,39.7,39.1,38.6,37.4,36.9,32.1,32.0,31.6,31.4,30.4,30.1,29.0,27.0,26.9,20.9,19.2,17.1,16.1,14.8;MS(ESI)m/z 661.4[M+H]+,683.2[M+Na]+;HRMS calcd.for C38H60O9Na 683.413 5,found 683.412 4。
1.2.4 化合物5的合成 稱取二糖基薯蕷皂苷4(34 mg,0.028mmol)于單口瓶中,加入吡啶(1.0mL),醋酐(1.0mL,10.6mmol)溶解樣品,室溫反應(yīng)過夜后,加入適量甲醇淬滅反應(yīng),旋蒸濃縮,二氯甲烷稀釋,有機(jī)相分別用1mol·L-1鹽酸,飽和碳酸氫鈉,蒸餾水,飽和食鹽水洗,無水硫酸鈉干燥,抽濾,濃縮,硅膠柱層析(石油醚∶乙酸乙酯∶二氯甲烷=7∶2∶1),濃縮,得無色透明漿狀物5(33mg,0.025mmol,91%)。[α]27D-63.6°(c 0.36,CHCl3);1H NMR (600MHz,CDCl3)δ5.35(m,2H),5.17(dd,1H,J=10.4,8.2Hz),5.02(dd,1H,J=10.4,3.3Hz),4.53(d,1H,J=8.3Hz),4.39(dd,1H,J=14.1,7.7Hz),4.16(dd,1H,J=11.0,7.1Hz),4.07(dd,1H,J=11.6,7.1Hz),3.90(t,1H,J=7.1Hz),3.45(m,2H),3.36(t,1H,J=11.0Hz),2.13(s,3H),2.05(s,3H),1.97(s,3H),1.16(s,9H),0.99(s,3H),0.96(d,3H,J=7.2Hz),0.78(d,3H,J=6.0Hz),0.77(s,3H);13C NMR (150MHz,CDCl3)δ178.0,170.3,169.5,140.4,122.0,109.4,100.4,80.9,80.4,77.3,77.1,76.9,71.1,70.6,69.2,67.1,66.9,62.2,61.3,56.5,50.1,41.7,40.3,39.8,39.0,37.2,36.9,32.1,31.5,30.4,29.6,28.9,27.1,20.9,20.8,20.7,19.4,17.2,16.4,14.6.MS (ESI):m/z 810.0 [M+Na]+;HRMS calcd.for C44H66O12Na 809.4452,found 809.4475。1.2.5化合物6的合成 向裝有新活化4A分子篩的封管中加入半乳糖薯蕷皂苷4(100mg,0.15mmol),無水二氯甲烷(4.0mL)溶解樣品,室溫攪拌1h,加入TMSOTf的二氯甲烷溶液(210μL,0.21mmol/L,0.04mmol),緩慢滴加N-苯基三氟亞胺酯9的二氯甲烷溶液(152mg,0.20mmol),室溫攪拌反應(yīng)3.5h后,加入2滴三乙胺淬滅反應(yīng),過濾,濃縮,硅膠柱層析(二氯甲烷∶乙酸乙酯=6∶1),濃縮得無色透明漿狀物6(56mg,0.046mmol,30%)。[α]27D+8.2°(c 0.80,CHCl3);1H NMR (600MHz,CDCl3)δ8.00(dd,2H,J=6.6,1.6Hz),7.96(dd,2H,J=7.1,1.7Hz),7.87(dd,2H,J=7.1,1.1Hz),7.82(dd,2H,J=8.2,1.1Hz),7.54-7.37(m,8H),7.31(t,2H,J=8.3Hz),7.27(t,2H,J=7.7Hz),5.93 (t,1H,J =9.9Hz),5.78 (t,1H,J=9.9Hz),5.54(dd,1H,J=9.4,7.7Hz),5.33(d,1H,J=7.7Hz),5.24(d,1H,J=5.0Hz),4.67(dd,1H,J=12.1,3.3Hz),4.48(m,2H),4.40(dd,1H,J=14.8,7.1Hz),4.22(m,3H),3.74(s,1H),3.66(t,1H,J=8.8Hz),3.59(m,3H),4.46(d,1H,J=6.1Hz),3.37(t,1H,J=10.4Hz),1.16(s,9H),0.97(d,3H,J=7.1Hz),0.95(s,3H),0.78(d,3H,J=6.6Hz),0.76(s,3H);13C NMR(150MHz,CDCl3)δ178.4,166.5,166.1,165.9,165.2,140.2,133.7,133.5,133.3,133.1,129.9,128.9,128.6,128.5,128.4,121.9,109.4,101.5,100.9,80.9,80.4,80.0,73.4,72.8,72.6,71.9,69.4,68.3,66.9,62.7,62.2,56.5,50.0,41.7,40.3,39.8,39.2,38.8,37.2,36.9,32.0,31.9,31.5,31.4,30.4,30.0,28.9,27.2,20.9,19.4,17.2,16.3,14.6;MS(ESI):m/z1261.9[M+Na]+.HRMS calcd.for C72H86O18Na 1261.571 2,found 1261.574 2。
1.2.6 化 合 物7的 合 成 化 合 物6(34mg,0.027mmol)經(jīng)采用與化合物5相同的合成條件得化合物7(33mg,0.025mmol,90%)。[α]27D-13.1°(c 0.42,CHCl3);1H NMR (600MHz,CDCl3)δ8.00(d,2H,J=7.1Hz),7.91(d,2H,J=7.1Hz),7.85(d,2H,J=7.1Hz),7.80(d,2H,J=7.1Hz),7.53-7.36(m,8H),7.31(t,2H,J=8.3Hz),7.27(t,2H,J=7.7Hz),5.86 (t,1H,J=9.4Hz),5.78(t,1H,J=9.9Hz),5.51(dd,1H,J=9.3,7.7Hz),5.29(d,1H,J=7.7Hz),5.24(d,1H,J=4.9Hz),5.21(d,1H,J=3.3Hz),4.87(dd,1H,J=10.4,3.3Hz),4.66(dd,1H,J=12.1,3.3Hz),4.60(d,1H,J=7.7Hz),4.49(dd,1H,J=12.1,3.8Hz),4.41(dd,1H,J=15.4,7.1Hz),4.18(m,1H),4.09(dd,1H,J=11.0,6.6Hz),4.00(dd,1H,J=11.0,6.6Hz),3.89(dd,1H,J=9.9,7.7Hz),3.83(t,1H,J=6.6Hz),3.59(m,1H),3.47(d,1H,J=8.3Hz),3.37(t,1H,J=11.0Hz),1.74(s,3H),1.71(s,3H),1.23(s,9H),0.97(d,3H,J=7.1Hz),0.95(s,3H),0.78(d,3H,J=6.6Hz),0.76(s,3H);13C NMR (150MHz,CDCl3)δ177.9,170.0,166.2,166.0,165.1,164.9,139.9,133.3,129.8,129.5,129.3,128.9,128.8,128.5,128.3,109.4,80.9,73.3,73.2,72.5,69.3,56.5,50.0,40.3,39.8,37.1,36.9,31.4,30.4,27.1,20.9,19.4,16.4,14.4;MS (ESI)m/z 1345.8 [M+Na]+;HRMS calcd.for C76H90O20Na 1345.592 3,found 1345.591 4。1.2.7化合物8的合成 稱取化合物7(20mg,0.015mmol),LiOH·H2O(6.88mg,0.16mmol)于單口瓶中,加入甲醇(6.0mL),四氫呋喃(0.6mL),水(75μL)溶解樣品,置于50℃油浴反應(yīng)過夜,酸性樹脂調(diào)節(jié)pH值到近中性,抽濾濃縮,硅膠柱層析(二氯甲烷∶甲醇∶水=6∶1∶0.08)后濃縮得白色固體8(11 mg,0.015mmol,99%)。[α]27D-45.2°(c 0.13,CH3OH);1H NMR (600MHz,pyridine-d5)δ5.30(s,1H),5.17(d,1H,J=8.2Hz),5.01(d,1H,J=7.1Hz),4.65-4.40(m,7H),4.29(t,2H,J=8.2Hz),4.17(t,1H,J=9.4Hz),4.12(t,1H,J=7.7Hz),4.04(t,1H,J=6.1Hz),3.88(m,2H),3.57(m,1H),3.48(t,1H,J=10.4Hz),1.12(d,3H,J=7.1Hz),0.97(s,3H),0.80(s,3H),0.67 (s,3H);13C NMR (150MHz,pyridine-d5)δ140.2,120.6,108.4,105.9,101.0,82.4,80.2,78.4,77.8,77.2,76.0,75.7,74.1,70.6,68.8,66.0,62.0,61.8,61.4,55.8,49.4,41.1,39.6,39.0,38.4,36.6,36.2,31.4,30.9,30.8,29.7,29.5,28.4,20.3,18.6,16.5,15.5,14.2.MS(ESI):m/z761.4[M+Na]+;HRMS calcd.for C39H62O13Na 761.408 3,found 761.409 5。
圖1 二糖基薯蕷皂苷8的合成Fig.1 Synthesis of diosgenyl diglycoside 8
薯蕷皂苷元與半乳糖給體1進(jìn)行糖苷化反應(yīng)后,經(jīng)脫保護(hù)方便地得到化合物3(見圖1)。接著對在化合物3的6′位引入特戊?;≒iv)保護(hù)基的反應(yīng)條件進(jìn)行了探索。首先,以CH2Cl2和pyridine為混合溶劑,3與1.5當(dāng)量的特戊酰氯在-40℃進(jìn)行反應(yīng),TLC檢測顯示反應(yīng)進(jìn)行緩慢;于是升高溫度到-15℃,增加PivCl的當(dāng)量到3.0,繼續(xù)反應(yīng)10h后,以20%收率得到化合物4(見圖1)。Kim等[8]報道了用BBTZ選擇性的保護(hù)伯羥基的方法,本文用1-羥基苯并三唑特戊酸酯在三乙胺存在下與化合物3反應(yīng),TLC顯示它對底物3的區(qū)域選擇性不好,收率約為20%。進(jìn)一步查閱文獻(xiàn)[9]發(fā)現(xiàn)在低溫條件下,以collidine作為反應(yīng)的溶劑和堿,能夠選擇性地在葡萄糖的6位引入乙?;Wo(hù)基。這樣,改用collidine為堿,在-5~35℃條件下,3與2.0當(dāng)量的特戊酰氯反應(yīng),TLC檢測表明反應(yīng)的區(qū)域選擇性比較好,但原料有剩余,增加PivCl的用量,原料仍反應(yīng)不完全。接著對反應(yīng)溫度進(jìn)行考察發(fā)現(xiàn),升高溫度到70℃,原料基本反應(yīng)完畢,最終以70%的收率得到了目標(biāo)化合物4;在此基礎(chǔ)上,對該反應(yīng)溫度進(jìn)一步優(yōu)化表明,在50和60℃下進(jìn)行該反應(yīng),收率并沒有大的改觀,分別為71%和68%。為了確定化合物4的結(jié)構(gòu),將其進(jìn)行全乙?;玫交衔?(見圖1)。與化合物4的相比,化合物5的1H-NMR譜圖顯示半乳糖2,3,4位的氫原子向低場位移至5.17,5.02,5.35ppm,從而確證了化合物4的結(jié)構(gòu)。
在糖化學(xué)的合成研究中,通常利用半乳糖的平伏鍵3-OH和直立鍵4-OH處于順式的關(guān)系,對3-OH進(jìn)行選擇性的保護(hù)和糖苷化,從而減少保護(hù)基操作,提高合成的效率[9]。于是在得到化合物4后,為了在其3-OH選擇性地引入葡萄糖基,所以作者對該糖苷化反應(yīng)進(jìn)行了研究。首先以TMSOTf或BF3·OEt2作為促進(jìn)劑,在不同溫度(-78或-40℃)下,化合物4與葡萄糖基三氯亞胺酯給體10(見圖1)反應(yīng),均沒有產(chǎn)物生成;當(dāng)改用三氟乙酰亞胺酯9作為糖基給體后,以TMSOTf為促進(jìn)劑,在-40℃~室溫條件下以30%的收率得到二糖苷化產(chǎn)物,由于1H-NMR譜圖復(fù)雜,不能清晰地顯示糖苷化發(fā)生位置,為了進(jìn)一步確定其結(jié)構(gòu),將其進(jìn)行全乙?;Wo(hù)得到化合物7。通過化合物7的1H-1H COSY 可以確定半乳糖環(huán)上氫的化學(xué)位移是H-1′(δH4.61),H-2′(δH3.89),H-3′(δH4.87),H-4′(δH5.21),H-5′(δH3.83),H-6-(δH4.09,4.00),而葡萄糖環(huán)上氫的化學(xué)位移 H-1″(δH5.30),H-2″(δH5.51),H-3″(δH5.86),H-4″(δH5.78),H-5″(δH4.18),H-6″(δH4.66,4.49);結(jié)合化合物7的 HMQC譜圖,確定了半乳糖環(huán)中碳原子的化學(xué)位移為 C-1′(δc101.5),C-2′(δc76.0),C-3′(δc71.9),C-4′(δc66.8),C-5′(δc70.2),C-6′(δc61.2);葡萄糖環(huán)中碳原子的化學(xué)位移為 C-1″(δc100.8),C-2″(δc72.3),C-3″(δc73.1),C-4″(δc69.2),C-5″(δc72.3),C-6″(δc62.0)。這樣通過化 合 物 7 的 HMBC 譜中 H-1″(δH5.30)與 C-2′(δc76.0)的相關(guān)峰,表明該條件下糖苷化發(fā)生在4中2′-OH,而不是期望的3′-OH。而文獻(xiàn)[10]報道,3的4-,6-OH用芐叉保護(hù)后得到化合物4a(見圖1)與給體10的糖苷化發(fā)生在其3′-OH上。這些結(jié)果表明糖苷化是一個非常微妙的反應(yīng),容易受到保護(hù)基、給體、促進(jìn)劑等多種因素影響,這無疑增加了糖類化合物合成的難度和不確定性。最后,化合物6經(jīng)LiOH處理,脫除保護(hù)基得二糖皂苷8。
以半乳糖三氯亞胺酯給體1和薯蕷皂苷元為原料,在高效地實現(xiàn)了對半乳糖苷2的6′-OH的特戊?;Wo(hù)的基礎(chǔ)上,采用選擇性糖苷化反應(yīng)策略,以5步反應(yīng),16%的總產(chǎn)率得到二糖皂苷8。目前在對該選擇性糖苷化反應(yīng)開展更深入的研究和應(yīng)用。
[1] Hostettmann K,Marston A.Saponins[M].New York:Cambridge Univercity Press,1995.
[2] David S,Veyrières A.A mild procedure for the regiospecific benzylation and allylation of polyhydroxy-compounds via their stannylene derivatives in non-polar solvents[J].J Chem Soc Perkin Trans,1981,1:1796-1801.
[3] Nashed,M A,Anderson L.Organotin derivatives and the selective acylation and alkylation of the equatorial hydroxy group in a vicinal,equatorial-axial pair [J].Tetrahedron Lett,1976,17(39):3503-3506.
[4] Tsuda Y,Haque M,Yoshimoto K.Regioselective monoacylation of some glycopyranosides via cyclic tin intermediates[J].Chem Pharm Bull,1983,31:1612-1624.
[5] Lubineau A,Lemoine R.Regioselective sulfation of galactose derivatives through the stannylene procedure.New synthesis of the 3′-O-sulfated Lewis trisaccharide[J].Tetrahedron Lett,1994,35:8795-8796.
[6] Ferreira F,Souli S,Vazquez A,et al.Steroid Saponin fromSolanum laxum [J].Phytochemistry,1996,42(5):1409-1416.
[7] Yoshikawa M,Kumahara A,Morikawa T,et al.Structures of steroidal alkaloid oligoglycosides,robeneosides A and B,and antidiabetogenic constituents from the brazilian Medicinal plant solanum lycocarpum [J].J Nat Prod,2007,70(2):210-214.
[8] Kim S,Chang H,Kim W J.Selective benzoylation of diols with 1-(benzoyloxy)benzotriazole [J].J Org Chem,1985,50(10):1751-1752.
[9] Hakki Z,Cao B,Goodger J Q D,et al.Synthesis of the monoterpenoid esters cypellocarpin C and cuniloside B and evidence for their widespread occurrence in Eucalyptus [J].Carbohydr Res,2010,345(14):2079-2084.
[10] Gu G,Du Y,Robert J L.Facile Synthesis of Saponins Containing 2,3-branched Oligosaccharides by Using Partially Protected Glycosyl Donors[J].J Org Chem,2004,69:6035-6038.